TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12954519

Group type: EXPERIMENTAL
Intervention: Seasonale, 91-day extended cycle oral contraceptive (30 microg ethinyl estradiol / 150 microg levonorgestrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nordette-28, conventional 28-day oral contraceptive (30 microg ethinyl estradiol / 150 microg levonorgestrel)
Number of subjects: 0
Study: 10740557

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1 bolus over 30 s and infusion at 0.5 microgram kg‐1 min‐1 with glycopyrolate 200 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microgram kg‐1 bolus over 30 s and infusion at 0.25 microgram kg‐1 min‐1 with glycopyrolate 200 micrograms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil 0.5 microgram kg‐1 bolus over 30 s and infusion at 0.25 microgram kg‐1 min‐1 without glycopyrolate
Number of subjects: 60
Study: 8623106

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside 300 mg intravenously, two doses before surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside
Number of subjects: 29
Study: 1594898

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 36
Study: 27786012

Group type: EXPERIMENTAL
Intervention: Enalapril 20 and 40 mg o.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 and 100 mg o.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: HCTZ (25 or 50 mg o.d. added if necessary)
Number of subjects: 12
Study: 28380718

Group type: EXPERIMENTAL
Intervention: Older adults with preclinical AD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitively normal older adults without preclinical AD
Number of subjects: 20
Study: 29165093

Group type: EXPERIMENTAL
Intervention: C. tora (330 mg) three times a day
Number of subjects: 60
Study: 27212646

Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24435788

Group type: COMPARATOR
Intervention: Intravenous rehydration therapy (IVRT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Nasogastric rehydration therapy (NGRT)
Number of subjects: 97
Study: 22306046

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (n = 54)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 106
Study: 20109317

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (AZENS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Triamcinolone acetonide nasal spray (TANS)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both AZENS and TANS
Number of subjects: 132
Study: 17434019

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg administered 3 days before ovulation (Group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg administered 1 day before ovulation (Group B)
Number of subjects: 14
Study: 16220809

Group type: EXPERIMENTAL
Intervention: Vita 3D‐Master shade guide system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vita Classical shade guide system
Number of subjects: 42
Study: 12373601

Group type: EXPERIMENTAL
Intervention: 5‐FU‐containing regimens
Number of subjects: 263
Study: 15321118

Group type: EXPERIMENTAL
Intervention: Oxford position (group O)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sitting position followed by wedged supine position (group S)
Number of subjects: 60
Study: 7561554

Group type: EXPERIMENTAL
Intervention: Rifater daily for the first 2 months, followed by Rifinah daily for 4 months (2 Rifater/4 Rifinah)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Rifater supplemented by ethambutol daily for the first 2 months followed by thiacetazone and isoniazid daily for 6 months (2 Rifater EMB/6 HT)
Number of subjects: 199
Study: 2293363

Group type: EXPERIMENTAL
Intervention: Methylprednisolone infusion during surgery
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 28
Study: 7373086

Group type: EXPERIMENTAL
Intervention: Aerosolized amantadine (1.0 g/100 ml of distilled water)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerosolized amantadine
Number of subjects: 20
Study: 31182143

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 30 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 50
Study: 28583999

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (15-minute loading intravenous infusion followed by a 24-hour maintenance dose)
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Placebo (15-minute loading intravenous infusion followed by a 24-hour maintenance dose)
Number of subjects: 1700
Study: 25583727

Group type: EXPERIMENTAL
Intervention: Continuous administration of ceftazidime (loading dose of 20 mg/kg followed by 60 mg/kg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intermittent administration of ceftazidime (20 mg/kg over 30 min every 8 h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Continuous administration of ceftazidime
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intermittent administration of ceftazidime
Number of subjects: 34
Study: 24070232

Group type: EXPERIMENTAL
Intervention: Accredited exercise physiologist-coordinated resistance exercise program (12, 24, or 36 weeks)
Number of subjects: 180
Study: 21841207

Group type: EXPERIMENTAL
Intervention: 500 mg vernakalant twice daily
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 150 mg vernakalant
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 300 mg vernakalant
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 500 mg vernakalant
Number of subjects: 735
Study: 19089780

Group type: EXPERIMENTAL
Intervention: cicogna system
Number of subjects: 100

Group type: COMPARATOR
Intervention: conventional method (plastic basin)
Number of subjects: 100
Study: 17159764

Group type: EXPERIMENTAL
Intervention: Sciatic-femoral block with mepivacaine 1% (15 + 25 mL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unilateral spinal anesthesia with 7 mg of hyperbaric bupivacaine 0.5%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sciatic-femoral block
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unilateral spinal anesthesia
Number of subjects: 32
Study: 15709355

Group type: EXPERIMENTAL
Intervention: 30 degree tilt position
Number of subjects: 46

Group type: COMPARATOR
Intervention: 90 degree lateral and supine positions
Number of subjects: 46
Study: 11172834

Group type: COMPARATOR
Intervention: Group 0 (recombinant FSH containing no LH)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Group 1 (urinary FSH containing <1 IU of LH)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Group 25 (hMG containing 25 IU of LH)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Group 75 (hMG containing 75 IU of LH)
Number of subjects: 128
Study: 9209250

Group type: EXPERIMENTAL
Intervention: Fenoterol (1.5 microgram/min)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Propranolol (loading dose of 0.14 mg/kg over 20 minutes, followed by 0.63 micrograms/kg/min)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dobutamine and Fenoterol
Number of subjects: 46
Study: 8216018

Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of central corneal thickness
Number of subjects: 450
Study: 3301861

Group type: EXPERIMENTAL
Intervention: Hydron‐AgSD (synthetic dressing with silver sulfadiazine 1%‐3%)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Silver sulfadiazine 1% only (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hydron‐AgSD (synthetic dressing)
Number of subjects: 27
Study: 29594976

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Remifentanil (DR)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Midazolam-Remifentanil (MR)
Number of subjects: 198
Study: 27126186

Group type: EXPERIMENTAL
Intervention: Gefitinib + Pemetrexed
Number of subjects: 0
Study: 24664811

Group type: EXPERIMENTAL
Intervention: Higher social interaction scores with non-family members
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Being married
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher Hamilton Depression Rating Scale score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher number of persons in one's family social network
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher instrumental support scores
Number of subjects: 100
Study: 22766835

Group type: EXPERIMENTAL
Intervention: Fine structure processing (FSP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High-definition continuous interleaved sampling (HDCIS)
Number of subjects: 25
Study: 19781112

Group type: EXPERIMENTAL
Intervention: Cognitive decline trajectory
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Psychotic symptoms
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Initial MMSE and age
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: APOE 4
Number of subjects: 201
Study: 18335226

Group type: EXPERIMENTAL
Intervention: GnRH antagonist multidose protocol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard long agonist protocol
Number of subjects: 96
Study: 15866679

Group type: EXPERIMENTAL
Intervention: Diltiazem treatment
Number of subjects: 10
Study: 12873686

Group type: EXPERIMENTAL
Intervention: Strontium-89 (Arm A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Saline (Arm B)
Number of subjects: 95
Study: 10476504

Group type: EXPERIMENTAL
Intervention: Endoscopic laser cycloablation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 58
Study: 8734342

Group type: EXPERIMENTAL
Intervention: Meal ingestion in phase I with an omelette labelled with 99mTc and 150 ml water labelled with 111In
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Meal ingestion in phase II with an omelette labelled with 99mTc and 150 ml water labelled with 111In
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phase I
Number of subjects: 12
Study: 2014891

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1.5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6175947

Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 6429677

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (5 mg, i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30272457

Group type: EXPERIMENTAL
Intervention: Beat gesture (speech accompanied by simple rhythmic gestures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iconic‐deictic gesture (speech accompanied by iconic and deictic gestures)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No gesture (speech only)
Number of subjects: 0
Study: 26812618

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 30
Study: 24750797

Group type: EXPERIMENTAL
Intervention: Probiotic preparation (Lactobacillus paracasei ssp.paracasei CRL‐431, Bifidobacterium BB‐12, Streptococcus thermophilus TH‐4, fructooligosaccharide)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 22300834

Group type: EXPERIMENTAL
Intervention: 250 g raw carrots
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 g cooked carrots
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 g cooked carrots
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acylated anthocyanins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-acylated anthocyanins
Number of subjects: 12
Study: 20486839

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide with methylprednisolone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cyclosporine with methylprednisolone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lisinopril (control)
Number of subjects: 28
Study: 18336681

Group type: EXPERIMENTAL
Intervention: MM Nutrition Curriculum
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 576
Study: 15963088

Group type: EXPERIMENTAL
Intervention: DP‐b99 (1.0 mg kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12459663

Group type: COMPARATOR
Intervention: Ondansetron (4 mg intravenous) with sham ReliefBand
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acustimulation with ReliefBand (2 ml intravenous saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of ondansetron (4 mg intravenous) and ReliefBand
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (sham treatment)
Number of subjects: 90
Study: 10530769

Group type: EXPERIMENTAL
Intervention: 11beta-HSD 1 expression and NNK carbonyl reductase activity in human lung
Number of subjects: 0
Study: 7485007

Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg t.i.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levosulpiride
Number of subjects: 40
Study: 1775884

Group type: EXPERIMENTAL
Intervention: Progestogen treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Contraceptive pill treatment
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 129
Study: 7008592

Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: J5 vaccine
Number of subjects: 136
Study: 30629609

Group type: EXPERIMENTAL
Intervention: Welfare rights advice and assistance with benefit entitlements delivered in participants’ homes by trained advisors
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Welfare rights advice and assistance with benefit entitlements
Number of subjects: 755

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 755
Study: 30290276

Group type: EXPERIMENTAL
Intervention: WebMAP mobile intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 27491227

Group type: EXPERIMENTAL
Intervention: Cangfu Congxian Decoction (CCD) 200 mL, twice daily for 2 months before IVF-ET
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group 1 (no treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group 2 (20 patients with tubal factors, no treatment)
Number of subjects: 40
Study: 24477109

Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Post hoc analysis of patients with no stroke
Number of subjects: 35
Study: 22992303

Group type: EXPERIMENTAL
Intervention: Carfilzomib (28‐day cycles at 20 mg/m(2) IV on Days 1‐2 of Cycle 1, escalating to 27 mg/m(2) IV on Days 8, 9, 15, and 16 and continuing at 27 mg/m(2) through Cycle 9 and Days 1, 2, 15, and 16 ≥ Cycle 10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC) regimen (corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional cyclophosphamide 50 mg PO once daily)
Number of subjects: 0
Study: 20456478

Group type: EXPERIMENTAL
Intervention: Telmisartan (20‐40 mg daily)
Number of subjects: 35
Study: 17381666

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Risperidone 4 mg alone
Number of subjects: 10
Study: 16285384

Group type: EXPERIMENTAL
Intervention: Synchronous detection of cardiac, respiratory, and snoring sounds using a microphone connected to a chestpiece applied to the heart region.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Principal component analysis of event-based characteristics of sound signals.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acoustic analysis for patient assessment.
Number of subjects: 30
Study: 11318529

Group type: EXPERIMENTAL
Intervention: Fibrate derivatives (predominantly fenofibrate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HMG‐CoA reductase inhibitors (simvastatin and pravastatin)
Number of subjects: 0
Study: 9596550

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 8843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8843
Study: 7943104

Group type: EXPERIMENTAL
Intervention: Expectant management for 48 hours
Number of subjects: 262

Group type: COMPARATOR
Intervention: Induction of labor 8 hours after premature rupture of membranes
Number of subjects: 262
Study: 3210656

Group type: EXPERIMENTAL
Intervention: Combined therapy (multimodal therapy including surgical resection, polychemotherapy, and radiation therapy)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 132

Group type: COMPARATOR
Intervention: Not eligible for treatment (maximal supportive care)
Number of subjects: 132
Study: 31764266

Group type: EXPERIMENTAL
Intervention: Trauma-Informed Adherence-Enhanced CBT (TI-CBTe) delivered by Rwandan youth leaders over 2 months for a total of 12 hours
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 356
Study: 28972629

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 181
Study: 25873601

Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard care
Number of subjects: 862

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Acupuncture (≥10 sessions)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 862
Study: 24235899

Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: AHI ≥ 15
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Insomnia subtypes
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Snoring loudness, snoring frequency, witnessed breathing pauses
Number of subjects: 435
Study: 21410420

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg three times daily for 8 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo three times daily for 8 days
Number of subjects: 25
Study: 19841706

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 380

Group type: COMPARATOR
Intervention: Landmark-guided technique
Number of subjects: 380
Study: 17305253

Group type: EXPERIMENTAL
Intervention: Rituximab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0
Study: 14980363

Group type: EXPERIMENTAL
Intervention: Assessment and case management for 6 months (treatment group)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group provided a list of available services
Number of subjects: 188
Study: 11751188

Group type: EXPERIMENTAL
Intervention: SpiroGame
Number of subjects: 102

Group type: COMPARATOR
Intervention: Candle-blowing
Number of subjects: 102
Study: 9358379

Group type: EXPERIMENTAL
Intervention: Peer incentives (reward for returning signed forms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No peer incentives (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desire to be protected
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual rewards
Number of subjects: 0
Study: 8406323

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day for 1 month
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3543231

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg q.d.)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg b.i.d.)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg q.d.) plus hydrochlorothiazide (25 mg)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 29985080

Group type: EXPERIMENTAL
Intervention: MTX + adalimumab (n = 89)
Number of subjects: 180

Group type: COMPARATOR
Intervention: MTX + placebo (n = 91)
Number of subjects: 180
Study: 28296012

Group type: EXPERIMENTAL
Intervention: Procedure-specific consent form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 0
Study: 25794984

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24295237

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDSS-C scores
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PDSS-C change scores
Number of subjects: 60
Study: 23250176

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (0.12%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Microwave sterilization (7 minutes)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sterile tap water
Number of subjects: 120
Study: 20002116

Group type: EXPERIMENTAL
Intervention: Home stimulation programme updated every 3 months, including activities to promote motor, cognitive, and speech and language development.
Number of subjects: 122

Group type: COMPARATOR
Intervention: No developmental intervention (comparison group).
Number of subjects: 122
Study: 18777846

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15727504

Group type: EXPERIMENTAL
Intervention: 30 mg oral methylphenidate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: triazolam
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 12576803

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0